Drugs / US Neulasta
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03251339 | Aug 2017 → Feb 2018 | — | Fresenius Kabi SwissBioSim GmbH | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04651036 Comparator | Nov 2020 → Nov 2021 | — | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | US Neulasta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04651036 ↗ |
| Route | Subcutaneous | “Participants received a single subcutaneous injection of US-Neulasta 6 mg/0.6 mL on Day 1 in morning of treatment period 1 and 2. Period 1 and Period 2 are separated by a...” NCT03251339 ↗ |